Bayer has agreed to pay $7.25 billion to settle Roundup cancer lawsuits, with individual payouts expected to range from $10,000 to $165,000 depending on the severity of each claimant’s case. The proposed class settlement, announced on February 17, 2026, covers more than 125,000 plaintiffs who allege that exposure to the glyphosate-based weedkiller caused them to develop non-Hodgkin lymphoma. Some claimants with the most serious cases — younger individuals with aggressive cancers tied to occupational exposure — could receive upwards of $198,000. Bayer is not admitting liability and continues to maintain that Roundup does not cause cancer, but the sheer volume of litigation has made settlement the pragmatic path forward.
The deal received preliminary approval from the 22nd Judicial Circuit Court of Missouri on March 4, 2026, though the formal claims process has not yet opened. This is not a quick payout situation — Bayer plans to fund the $7.25 billion through annual payments spread over 17 to 21 years, not a single lump sum. Meanwhile, the U.S. Supreme Court is preparing to hear oral arguments in April 2026 on whether EPA approval of Roundup should preempt state-court failure-to-warn claims, a ruling that could reshape the legal landscape for pending and future cases. This article breaks down the payout tiers, who qualifies, how the timeline works, and what claimants should realistically expect.
Table of Contents
- How Are Bayer Roundup Settlement Payouts Between $10,000 and $165,000 Determined?
- Who Qualifies for the Roundup Settlement and What Are the Eligibility Requirements?
- Why Is Bayer Paying $7.25 Billion Over 17 to 21 Years Instead of a Lump Sum?
- How to File a Roundup Settlement Claim — Practical Steps and Tradeoffs
- The Supreme Court Wild Card — How April 2026 Arguments Could Change Everything
- What Roundup Claimants Can Learn from Previous Settlement Payouts
- What Happens Next for Roundup Litigation and Future Claimants
- Conclusion
- Frequently Asked Questions
How Are Bayer Roundup Settlement Payouts Between $10,000 and $165,000 Determined?
The settlement uses a nine-tier system to calculate individual payouts, and the differences between tiers are significant. Three primary factors determine where a claimant lands: the type of exposure (occupational versus residential), age at diagnosis, and whether the cancer is classified as fast-growing or slow-growing. A 45-year-old landscaper diagnosed with an aggressive form of non-Hodgkin lymphoma after years of daily Roundup use would be placed in a substantially higher tier than a 70-year-old homeowner who occasionally sprayed weeds in the garden and developed an indolent lymphoma. Past individual Roundup verdicts have ranged from $10,000 to over $1 million, but those were jury awards in standalone trials — not settlement payouts from a class fund. The class settlement compresses that range considerably. Most claimants should expect something between $10,000 and $165,000, with the majority likely landing somewhere in the middle tiers.
The top-end figure of $198,000 or more is reserved for the most compelling cases. One important caveat: attorney fees will reduce the net amount claimants actually receive. Most Roundup lawyers work on contingency, typically taking 33% to 40% of the settlement amount, which means a $100,000 gross payout could translate to $60,000 to $67,000 in the claimant’s pocket. The tier system is designed to prevent the kind of protracted individual negotiations that have bogged down Roundup litigation for years. But it also means that claimants with genuinely extraordinary circumstances — someone who used Roundup professionally for decades and developed multiple cancers, for instance — may feel the settlement undervalues their case. Those individuals may choose to opt out and pursue standalone litigation, though that carries its own risks and delays.
Who Qualifies for the Roundup Settlement and What Are the Eligibility Requirements?
Eligibility for the $7.25 billion settlement covers two broad groups: current plaintiffs with pending Roundup lawsuits and future claimants who have not yet filed but meet the criteria. The key requirements are straightforward but specific. You must have been exposed to Roundup before mid-February 2026, and you must have been diagnosed — or be diagnosed within 16 years of the court’s final approval — with non-Hodgkin lymphoma. Other cancers are not covered under this settlement, even if a claimant believes Roundup contributed to their illness. However, meeting the basic eligibility criteria does not guarantee a large payout or even participation in the settlement. Law firms representing approximately 20,000 plaintiffs pushed back against the deal, urging the Missouri judge to delay review and arguing it should not be fast-tracked.
Their concern is that some plaintiffs with strong individual cases would receive far less under the class settlement than they might in a standalone trial. If you have a pending case with an attorney, that attorney may advise you to opt out of the class settlement entirely. This is a real tension in the case — what is efficient for resolving mass litigation is not necessarily optimal for every individual plaintiff. Future claimants face an additional wrinkle. The 16-year diagnostic window means that someone exposed to Roundup in, say, 2020 who develops non-Hodgkin lymphoma in 2045 would likely fall outside the settlement’s coverage. Given that some forms of NHL can take decades to develop after chemical exposure, this cutoff is a genuine limitation. Anyone with significant Roundup exposure history who has not been diagnosed should be aware of this timeline and consult with a physician about monitoring.
Why Is Bayer Paying $7.25 Billion Over 17 to 21 Years Instead of a Lump Sum?
bayer structured the settlement as annual payments over 17 to 21 years for a simple reason: paying $7.25 billion at once would be financially devastating. The company has already spent billions on previous Roundup settlements and legal defense costs, and it estimates approximately €5 billion in litigation-related payouts in 2026 alone. Spreading payments over two decades allows Bayer to manage cash flow while continuing to operate its agricultural, pharmaceutical, and consumer health businesses. For a company that acquired Monsanto for $63 billion in 2018 — a deal that many analysts now consider one of the worst corporate acquisitions in history — the extended payment schedule is a matter of survival, not stinginess. For claimants, this structure means delays. Even after the formal claims process opens and individual payouts are calculated, the money will flow according to the payment schedule rather than arriving as a single check.
The court will establish priority rules for which claimants get paid first, and those in the highest tiers or with the most urgent medical situations will likely be front of the line. But someone in a lower tier could be waiting years after final approval before seeing their settlement funds. This is a critical distinction from the headline numbers — $10,000 that arrives in 2030 is worth less in real terms than $10,000 today. Bayer’s 2018 acquisition of Monsanto brought with it roughly 200,000 Roundup-related claims. The company had previously set aside $10.9 billion in 2020 to resolve the first wave of cases, but litigation continued to mount. The $7.25 billion figure represents Bayer’s attempt to draw a definitive line under the Roundup saga, but whether it succeeds depends on the Supreme Court ruling, the opt-out rate among current plaintiffs, and whether future claimants find the terms acceptable.
How to File a Roundup Settlement Claim — Practical Steps and Tradeoffs
As of March 2026, the formal claim filing process has not yet opened. Preliminary approval was granted on March 4, 2026, but several steps remain before claimants can submit paperwork. The court must schedule a fairness hearing, notify all potential class members, allow an opt-out period, and then grant final approval before the claims process formally begins. Realistically, this timeline means most claimants should not expect to file claims until late 2026 at the earliest. When the process does open, claimants will need to document their Roundup exposure history and non-Hodgkin lymphoma diagnosis. Medical records, employment records (for occupational exposure), purchase receipts, and physician testimony all strengthen a claim.
The tradeoff every claimant faces is whether to participate in the class settlement or opt out and pursue individual litigation. Participating in the settlement offers certainty — a guaranteed payout within a defined range — but at a potentially lower amount than a jury might award. Opting out preserves the chance for a larger verdict but also carries the risk of losing at trial and receiving nothing, plus years of additional legal proceedings. For most people, especially those dealing with active cancer treatment, the guaranteed settlement payment is the more practical choice. If you have already retained a Roundup attorney, they should be communicating directly with you about the settlement terms and your options. If you have not yet retained counsel, be cautious about law firms aggressively advertising Roundup settlement services — the legitimate claims process will be administered through the court, not through marketing campaigns.
The Supreme Court Wild Card — How April 2026 Arguments Could Change Everything
The U.S. Supreme Court is preparing to hear oral arguments in April 2026 on a question that could fundamentally alter the Roundup litigation landscape: does the EPA’s approval of Roundup without a cancer warning label preempt state-court failure-to-warn claims? If the Court sides with Bayer, it could effectively shut down the legal theory underlying most Roundup lawsuits — that Monsanto failed to warn consumers about cancer risks. Such a ruling would not necessarily void the $7.25 billion settlement, which is a negotiated agreement, but it would dramatically weaken the bargaining position of anyone who opted out to pursue individual claims. This is a serious risk that every claimant should factor into their decision.
The legal consensus before 2026 largely favored plaintiffs on the preemption question, but the current Court has shown willingness to limit state-level consumer protection claims in favor of federal regulatory frameworks. If you are considering opting out of the settlement to chase a larger individual verdict, the Supreme Court’s pending decision is the single biggest variable in that calculus. A pro-Bayer ruling in June or July 2026 could leave opt-out plaintiffs with severely diminished claims and no settlement safety net to fall back on. Conversely, if the Court rejects Bayer’s preemption argument, the company could face a new wave of litigation from claimants emboldened by the ruling. That scenario might actually make the $7.25 billion settlement look like a bargain for Bayer — and a worse deal for plaintiffs who accepted it.
What Roundup Claimants Can Learn from Previous Settlement Payouts
Bayer’s earlier rounds of Roundup settlements provide some instructive precedent. The company’s 2020 settlement of approximately $10.9 billion resolved roughly 100,000 claims, which works out to an average of around $109,000 per claim — though actual payouts varied enormously based on case strength. Some plaintiffs who went to trial won verdicts of $80 million or more, though those were reduced on appeal. The current $7.25 billion settlement covering over 125,000 plaintiffs works out to a lower per-claimant average of approximately $58,000, reflecting the inclusion of weaker claims and future claimants who have not yet been diagnosed.
That math underscores why some plaintiff attorneys are pushing back. If you have a strong case — occupational exposure, clear diagnosis, limited alternative risk factors — the class settlement may undervalue your claim compared to what earlier plaintiffs received. But earlier plaintiffs also waited years for resolution, and some received nothing after losing at trial. The settlement represents a tradeoff between speed and certainty on one hand, and maximum potential recovery on the other.
What Happens Next for Roundup Litigation and Future Claimants
The next twelve months will be decisive for the Roundup settlement. The Supreme Court’s ruling, expected by late June 2026, will either reinforce or undermine the legal foundation of Roundup cancer claims. The Missouri court’s final approval process will determine whether enough plaintiffs participate to make the class settlement viable — if too many opt out, Bayer could withdraw the offer entirely. And the first wave of actual claim processing will reveal whether the nine-tier system produces payouts that claimants consider fair.
For people who were exposed to Roundup but have not been diagnosed with non-Hodgkin lymphoma, the settlement’s 16-year future claimant window is both a safety net and a ticking clock. Regular medical checkups and awareness of NHL symptoms — unexplained weight loss, persistent fatigue, swollen lymph nodes — are important for anyone with significant exposure history. The science around glyphosate and cancer risk remains contested, with the International Agency for Research on Cancer classifying it as “probably carcinogenic” while the EPA maintains it is not likely to cause cancer. That regulatory disagreement is exactly what the Supreme Court case will attempt to resolve.
Conclusion
The Bayer $7.25 billion Roundup settlement represents the largest single resolution in the long-running glyphosate litigation saga, but the devil is in the details. Payouts ranging from $10,000 to $165,000 — and potentially up to $198,000 — will be distributed through a nine-tier system based on exposure type, age at diagnosis, and cancer severity. The extended payment schedule of 17 to 21 years means claimants should temper expectations about receiving quick payouts. With the formal claims process not yet open and the Supreme Court poised to weigh in on the underlying legal theory, nothing is fully settled despite the preliminary court approval.
If you or a family member used Roundup and have been diagnosed with non-Hodgkin lymphoma, the most important step right now is ensuring you have competent legal representation and complete medical documentation. Do not sign anything or agree to any terms without consulting an attorney familiar with the Roundup litigation. Watch the Supreme Court docket for the April 2026 oral arguments and the subsequent ruling, as that decision will significantly influence whether participating in the class settlement or pursuing individual litigation is the better path. The claims window will open eventually — use the intervening time to prepare your documentation and make an informed decision.
Frequently Asked Questions
When can I file a claim for the Roundup settlement?
The formal claim process has not yet opened as of March 2026. Preliminary approval was granted on March 4, 2026, but final approval, a fairness hearing, and the establishment of a claims administration process must occur first. Realistically, claim filing is unlikely to begin before late 2026.
How much will I receive from the Roundup settlement?
Individual payouts are expected to range from $10,000 to $165,000, with some cases potentially reaching $198,000 or more. Your specific amount depends on which of the nine tiers you are placed in, based on your exposure type, age at diagnosis, and cancer aggressiveness. Attorney fees will further reduce your net payout.
Do I qualify for the Roundup settlement if I used it at home?
Yes, residential users are eligible, not just agricultural or occupational users. However, residential users are generally placed in lower payout tiers than those with occupational exposure. You must have been exposed before mid-February 2026 and diagnosed with non-Hodgkin lymphoma.
Should I opt out of the class settlement and sue individually?
This depends on the strength of your individual case and your risk tolerance. Opting out preserves the possibility of a larger jury verdict but carries the risk of losing and receiving nothing. The pending Supreme Court case on federal preemption adds significant uncertainty. Consult your attorney before making this decision.
What if I was exposed to Roundup but haven’t been diagnosed with cancer yet?
The settlement includes a future claimant provision covering people diagnosed with non-Hodgkin lymphoma within 16 years of the court’s final approval. If you were exposed before mid-February 2026 and receive a qualifying diagnosis within that window, you may be eligible. Monitor your health and keep records of your Roundup exposure history.
Will the $7.25 billion be paid out all at once?
No. Bayer will fund the settlement through annual payments over 17 to 21 years. This means claimants in lower priority tiers may wait years after final approval before receiving their settlement funds.